• Affinity Purification• Ion Exchange• Size Exclusion

(Gel Filtration)• Hydrophobic Interaction

Chromatography• Mixed-Mode

Chromatography• Hydroxyapatite

Versatile offering for purification of biomolecules

BioSepra® Chromatography Media

Chromatography continues to be an essential technology for the purification of biomolecules. Pall offers an extensive portfolio of media for affinity, ionexchange, size exclusion, hydrophobic interaction and hydroxyapitite chromatography. We offer products to cover research needs, scale-up and polishing. Depending on your specific application needs, Pall offers chromatography solutions in resin and/or membrane form. We offer flat sheetmembranes, bulk resins or media incorporated into specific product housings.

Our chromatography medias can be used for purification of biomolecules (e.g.,nucleic acids, proteins) and compounds on the research and process scale. Ourresins are useful in proteomic sample preparation applications, as well as, inlaboratory bioprocessing development and scale-up work.For the full listing of chromatography technologies offered by Pall, please refer to the Pall Laboratory Filtration and Separation Catalog or visitwww.pall.com/lab.

© 2006, Pall Corporation. Pall, , Acrodisc, AcroPrep, BioSepra, Enchant, HyperCel, HyperD, HyperZ, Mustang, Trisacryl, and Ultrogel aretrademarks of Pall Corporation. ® indicates a trademark registered in the USA. is a service mark of Pall Corporation.

2/06, 1k, GN05.1149 PN 33400

For technical information visit us on the Web at www.pall.com/lab

Chromatography Pall Working Cleaning Pressure Type Product Description Part Number Size (mL) Particle Size Capacity pH pH Stability Applications

Size Exclusion Ultrogel® AcA 22 Ultrogel AcA are 23013-025 100 60-140 µm n.a. 3-10 3-10 Exclusion Limit Fractionation Range(Gel Filtration) Ultrogel AcA 22 polymeric sorbents for 23013-014 1000 60-140 µm n.a. 3-10 3-10 3,000 KD 100 - 1200 KD

Ultrogel AcA 34 size exclusion composed 23015-025 100 60-140 µm n.a. 3-10 3-10 750 KD 20 - 350 KDUltrogel AcA 34 of polyacrylamide 23015-019 1000 60-140 µm n.a. 3-10 3-10Ultrogel AcA 44 and agarose, characterized 23022-024 100 60-140 µm n.a. 3-10 3-10 200 KD 10 - 130 KDUltrogel AcA 44 by narrow particle 23022-015 1000 60-140 µm n.a. 3-10 3-10Ultrogel AcA 54 size distribution and narrow 23019-023 100 60-140 µm n.a. 3-10 3-10 90 KD 5 - 70 KDUltrogel AcA 54 pore size distribution. 23019-011 1000 60-140 µm n.a. 3-10 3-10

Separation by Ultrogel AcA 202 24892-022 100 60-140 µm n.a. 3-10 3-10 22 KD 1 - 15 KDMolecule Size Ultrogel AcA 202 24892-010 1000 60-140 µm n.a. 3-10 3-10

Trisacryl® GF05 M Trisacryl GF are highly 25914-060 100 40-80 µm n.a. 1-11 1-11 up to 3 bar Lowest exclusion limit, for desaltinghydrophilic copolymers designed (45 psi) and other small molecule removal

Trisacryl GF05 M for medium pressure gel filtration. 25914-037 1000 40-80 µm n.a. 1-11 1-11 up to 3 bar Lowest exclusion limit, for desalting(45 psi) and other small molecule removal

Trisacryl GF2000 LS 26065-045 100 80-160 µm n.a. 1-11 1-11 up to 3 bar Affinity chromatography,(45 psi) purification of macromolecules

Trisacryl GF2000 LS 26065-011 1000 80-160 µm n.a. 1-11 1-11 up to 3 bar Affinity chromatography,(45 psi) purification of macromolecules

Ion Exchange Bulk ResinQ Ceramic HyperD® 20 Strong anion exchanger. 20040-051 5 20 µm (avg) >85 mg/mL (4) 2-12 1-14 200 bar (3,000 psi) Polypeptide and plasmid purification

Ceramic HyperDQ Ceramic HyperD 20 ion exchangers 20040-044 25 20 µm (avg) >85 mg/mL (4) 2-12 1-14 200 bar (3,000 psi) Polypeptide and plasmid purification

employ a high capacity Q Ceramic HyperD 20 hydrogel polymerized within 20040-036 100 20 µm (avg) >85 mg/mL (4) 2-12 1-14 200 bar (3,000 psi) Polypeptide and plasmid purification

the large pores of aQ Ceramic HyperD 20 rigid ceramic bead. 20040-028 500 20 µm (avg) >85 mg/mL (4) 2-12 1-14 200 bar (3,000 psi) Polypeptide and plasmid purification Q Ceramic HyperD 20 20040-010 1000 20 µm (avg) >85 mg/mL (4) 2-12 1-14 200 bar (3,000 psi) Polypeptide and plasmid purification

S Ceramic HyperD 20 Strong cation exchanger. 20038-055 5 20 µm (avg) >85 mg/mL (5) 2-12 1-14 200 bar (3,000 psi) Polypeptide purification Ceramic HyperD ion

S Ceramic HyperD 20 exchangers employ a high 20038-048 25 20 µm (avg) >85 mg/mL (5) 2-12 1-14 200 bar (3,000 psi) Polypeptide purification capacity hydrogel polymerized

S Ceramic HyperD 20 within the large pores of a rigid 20038-030 100 20 µm (avg) >85 mg/mL (5) 2-12 1-14 200 bar (3,000 psi) Polypeptide purification S Ceramic HyperD 20 ceramic bead. 20038-022 500 20 µm (avg) >85 mg/mL (5) 2-12 1-14 200 bar (3,000 psi) Polypeptide purification S Ceramic HyperD 20 20038-014 1000 20 µm (avg) >85 mg/mL (5) 2-12 1-14 200 bar (3,000 psi) Polypeptide purification

Q Ceramic HyperD F Strong anion exchanger. 20066-098 5 50 µm (avg) >85 mg/mL (4) 2-12 1-14 70 bar (1,000 psi) Protein concentration, protein separation,Ceramic HyperD ion contaminant removal

Q Ceramic HyperD F exchangers employ a high 20066-031 25 50 µm (avg) >85 mg/mL (4) 2-12 1-14 70 bar (1,000 psi) Protein concentration, protein separation,capacity hydrogel polymerized plasmid, vaccines purification, capture step

Q Ceramic HyperD F within the large pores of 20066-023 100 50 µm (avg) >85 mg/mL (4) 2-12 1-14 70 bar (1,000 psi) Protein concentration, protein separation,a rigid ceramic bead. contaminant removal

Q Ceramic HyperD F 20066-015 1000 50 µm (avg) >85 mg/mL (4) 2-12 1-14 70 bar (1,000 psi) Protein concentration, protein separation,contaminant removal

S Ceramic HyperD F Strong cation exchanger. 20062-089 5 50 µm (avg) >75 mg/mL (5) 2-12 1-14 70 bar (1,000 psi) Protein concentration, protein separation,Ceramic HyperD ion contaminant removal

S Ceramic HyperD F exchangers employ a high 20062-030 25 50 µm (avg) >75 mg/mL (5) 2-12 1-14 70 bar (1,000 psi) Protein concentration, protein separation,capacity hydrogel polymerized contaminant removal

S Ceramic HyperD F within the large pores of 20062-022 100 50 µm (avg) >75 mg/mL (5) 2-12 1-14 70 bar (1,000 psi) Protein concentration, protein separation,a rigid ceramic bead. contaminant removal

20062-014 1000 50 µm (avg) >75 mg/mL (5) 2-12 1-14 70 bar (1,000 psi) Protein concentration, protein separation,contaminant removal

DEAE Ceramic HyperD F Weak anion exchanger. 20067-070 5 50 µm (avg) >85 mg/mL (4) 2-12 1-14 70 bar (1,000 psi) Protein concentration, protein separation,Ceramic HyperD ion contaminant removal

DEAE Ceramic HyperD F exchangers employ a high 20067-039 25 50 µm (avg) >85 mg/mL (4) 2-12 1-14 70 bar (1,000 psi) Protein concentration, protein separation,capacity hydrogel polymerized contaminant removal

DEAE Ceramic HyperD F within the large pores of 20067-021 100 50 µm (avg) >85 mg/mL (4) 2-12 1-14 70 bar (1,000 psi) Protein concentration, protein separation,a rigid ceramic bead. contaminant removal

DEAE Ceramic HyperD F 20067-013 1000 50 µm (avg) >85 mg/mL (4) 2-12 1-14 70 bar (1,000 psi) Protein concentration, protein separation,contaminant removal

Separation CM Ceramic HyperD F Weak cation exchanger. 20050-084 5 50 µm (avg) >60 mg/mL (6) 2-12 1-14 70 bar (1,000 psi) Protein concentration, protein separation,by charge Ceramic HyperD ion contaminant removal

CM Ceramic HyperD F exchangers employ a high 20050-035 25 50 µm (avg) >60 mg/mL (6) 2-12 1-14 70 bar (1,000 psi) Protein concentration, protein separation,capacity hydrogel polymerized contaminant removal

CM Ceramic HyperD F within the large pores of 20050-027 100 50 µm (avg) >60 mg/mL (6) 2-12 1-14 70 bar (1,000 psi) Protein concentration, protein separation,a rigid ceramic bead. contaminant removal

CM Ceramic HyperD F 20050-019 1000 50 µm (avg) >60 mg/mL (6) 2-12 1-14 70 bar (1,000 psi) Protein concentration, protein separation,contaminant removal

Q HyperZ® Strong anion exchanger on HyperZ 21012-010 50 g 75 µm (avg) >80 mg/mL (11) 4-13 1-14 Expanded bed and packed bed separationsQ HyperZ sorbents which are composed of 21012-020 250 g 75 µm (avg) >80 mg/mL (11) 4-13 1-14 Expanded bed and packed bed separations

stable porous zirconium oxide beadsfilled with a high charge-density, crosslinked hydrogel.

CM HyperZ Weak cation exchanger on HyperZ 21011-010 50 g 75 µm (avg) ~50 mg/mL (12) 4-13 1-14 Expanded bed and packed bed separationsCM HyperZ sorbents which are composed of 21011-020 250 g 75 µm (avg) ~50 mg/mL (12) 4-13 1-14 Expanded bed and packed bed separations

stable porous zirconium oxide beadsfilled with a high charge-density, crosslinked hydrogel.

DevicesAcroPrep™ 96 Strong anion exchange membrane in 5047 Protein concentration, protein separation,Mustang® Q, 350 µL a 96 multi-well filter plate configuration. contaminant removalAcroPrep 96 Strong anion exchange membrane in 5062 Protein concentration, protein separation,Mustang Q, 1 mL a 96 multi-well filter plate configuration. contaminant removalAcroPrep 96 Strong cation exchange membrane in 5048 Protein concentration, protein separation,Mustang S, 350 µL a 96 multi-well filter plate configuration. contaminant removalAcroPrep 96 Strong cation exchange membrane in 5063 Protein concentration, protein separation,Mustang S, 1 mL a 96 multi-well filter plate configuration. contaminant removal

Acrodisc® Mustang Q Strong anion exchange membrane MSTG25Q6 Protein concentration, protein separation,in a syringe filter configuration contaminant removal

Acrodisc Mustang S Strong cation exchange membrane MSTG25S6 Protein concentration, protein separation,in a syringe filter configuration contaminant removal

Affinity Bulk ResinBlue Trisacryl M Blue Trisacryl M is an affinity 25896-051 5 40-80 µm HSA: 10-15 mg/mL; 1-10 Albumin depletion

chromatographic sorbent used for BSA: 5-7 mg/mL (1)Blue Trisacryl M the purification of a wide variety of 25896-045 25 40-80 µm HSA: 10-15 mg/mL; 1-10 Albumin depletion

enzymes and proteins such as, kinases, BSA: 5-7 mg/mL (1)Blue Trisacryl M albumin, interferons and some 25896-010 100 40-80 µm HSA: 10-15 mg/mL; 1-10 Albumin depletion

coagulation factors.The basic matrix BSA: 5-7 mg/mL (1)Blue Trisacryl M is Trisacryl GF2000, a macroporous 25896-028 1000 40-80 µm HSA: 10-15 mg/mL; 1-10 Albumin depletion

non-ionic sorbent on which Cibacron BSA: 5-7 mg/mL (1)blue is covalently immobilized.

Protein A Ceramic Protein A Ceramic HyperD F is a 20078-036 5 50 µm (avg) >30 mg/mL (2) 2-11 IgG purification/depletionHyperD F high capacity affinity sorbent designedProtein A Ceramic for the purification/depletion of IgG. 20078-028 25 50 µm (avg) >30 mg/mL (2) 2-11 IgG purification/depletionHyperD F Protein A Ceramic HyperD F isProtein A Ceramic prepared using a rigid proprietary 20078-010 100 50 µm (avg) >30 mg/mL (2) 2-11 IgG purification/depletioHyperD F ceramic bead. Recombinant Protein AProtein A Ceramic is immobilized to a specially 20078-044 1000 50 µm (avg) >30 mg/mL (2) 2-11 IgG purification/depletionHyperD F formulated hydrogel within the

porous ceramic bead.

Heparin HyperD M Heparin HyperD M composite 20029-062 5 80 µm (avg) >25 mg/mL (3) 3-13 3-13 70 bar (1,000 psi) Purification of coagulation factors,chromatography sorbent is used to lipoproteins, growth hormones, growth purify biological molecules that bind factors, nucleic acid binding enzymes

Heparin HyperD M to heparin such as coagulation factors, 20029-039 25 80 µm (avg) >25 mg/mL (3) 3-13 3-13 70 bar (1,000 psi) Purification of coagulation factors,Separation using growth factors and lipoproteins. lipoproteins, growth hormones, growth specific ligands Heparin HyperD M is composed of a factors, nucleic acid binding enzymes

Heparin HyperD M porous rigid mineral bead containing 20029-021 100 80 µm (avg) >25 mg/mL (3) 3-13 3-13 70 bar (1,000 psi) Purification of coagulation factors,heparin (porcine) bound hydrogel lipoproteins, growth hormones, growth filled pores. factors, nucleic acid binding enzymes

Heparin HyperD M 20029-013 1000 80 µm (avg) >25 mg/mL (3) 3-13 3-13 70 bar (1,000 psi) Purification of coagulation factors,lipoproteins, growth hormones, growth factors, nucleic acid binding enzymes

Lysine HyperD Lysine HyperD is used to purify 20059-058 5 70 µm (avg) n.a. 3-13 3-13 70 bar (1,000 psi) Purification of glycoproteinsLysine HyperD biological molecules that bind to lysine 20059-036 25 70 µm (avg) n.a. 3-13 3-13 70 bar (1,000 psi) Purification of glycoproteinsLysine HyperD such as glycoproteins. Lysine HyperD 20059-028 100 70 µm (avg) n.a. 3-13 3-13 70 bar (1,000 psi) Purification of glycoproteinsLysine HyperD is comprised of a porous rigid mineral 20059-010 1000 70 µm (avg) n.a. 3-13 3-13 70 bar (1,000 psi) Purification of glycoproteins

bead containing lysine (L-lysine) bound hydrogel filled pores.

KitsEnchant™ Albumin For the depletion of albumin 5300-ALBDEP 25 reactions Albumin depletionDepletion Kit from plasma or serum.

Includes all buffer & devices needed for 25 purifications.

Enchant Protein A Kit For the purification of IgG. Includes 5300-IGGPROA 50 reactions lgG purification/depletionas buffers & devices needed for 50 purifications. for IgG Purification

Enchant Protein G Kit For the purification of IgG. Includes 5300-IGGPROG 10 reactions lgG purification/depletionas buffers & devices needed for10 purifications. for IgG Purification

Mixed Mode & Bulk ResinHydrophobic MEP HyperCel™ MEP HyperCel (4-mercapto-ethyl- 12035-069 5 80-100 µm >20 mg/mL (7) adsorption: 7.0-9.0 Purification/depletion of polyclonal & Charge pyridine) sorbent is specifically elution: 4.0-5.8 monoclonal antibodies from most speciesInduction (HCIC) MEP HyperCel designed for the capture and 12035-010 25 80-100 µm >20 mg/mL (7) adsorption: 7.0-9.0 Purification/depletion of polyclonal &

purification of monoclonal and elution: 4.0-5.8 monoclonal antibodies from most speciesMEP HyperCel polyclonal antibodies. In contrast 12035-028 100 80-100 µm >20 mg/mL (7) adsorption: 7.0-9.0 Purification/depletion of polyclonal &

to protein A sorbents, IgG binding elution: 4.0-5.8 monoclonal antibodies from most speciesMEP HyperCel on MEP HyperCel is essentially 12035-036 1000 80-100 µm >20 mg/mL (7) adsorption: 7.0-9.0 Purification/depletion of polyclonal &

independent of subclass or species. elution: 4.0-5.8 monoclonal antibodies from most species"Weakly binding" variants (e.g.,murine IgG, rat IgG) are well retained.

MBI HyperCel MBI HyperCel (2-mercapto-5- 20194-069 5 80-100 µm >20 mg/mL (8) adsorption: 5.0-5.5 Purification of monoclonal and benzimidazole sulfonic acid) is a elution: 8.0-9.5 polyclonal antibodies

MBI HyperCel mixed-mode sorbent designed for 20194-010 25 80-100 µm >20 mg/mL (8) adsorption: 5.0-5.5 Purification of monoclonal and the capture of monoclonal and elution: 8.0-9.5 polyclonal antibodies

MBI HyperCel polyclonal antibodies. 20194-028 100 80-100 µm >20 mg/mL (8) adsorption: 5.0-5.5 Purification of monoclonal and elution: 8.0-9.5 polyclonal antibodies

MBI HyperCel 20194-036 1000 80-100 µm >20 mg/mL (8) adsorption: 5.0-5.5 Purification of monoclonal and elution: 8.0-9.5 polyclonal antibodies

SDR HyperD SDR HyperD is a "mixed mode" of 20033-065 5 40-100 µm 60-80 mg/mL (13) 2-12 2-12 70 bar (1,000 psi) Solvent and detergent removalSDR HyperD size exclusion, normal phase and 20033-031 25 40-100 µm 60-80 mg/mL (13) 2-12 2-12 70 bar (1,000 psi) Solvent and detergent removalSDR HyperD reversed phase. It is a unique sorbent 20033-023 100 40-100 µm 60-80 mg/mL (13) 2-12 2-12 70 bar (1,000 psi) Solvent and detergent removalSDR HyperD designed to eliminate solvents and 20033-015 1000 40-100 µm 60-80 mg/mL (13) 2-12 2-12 70 bar (1,000 psi) Solvent and detergent removal

detergents while recovering NATIVE protein. SDR HyperD is a composite sorbent that combines a silica beadmoiety filled with long chain aliphaticpolymers that are cross-linked to provide a 3D mesh with a low size exclusion limit of 10 kDa which excludes proteins.

Hydroxyapatite Bulk ResinHA Ultrogel HA Ultrogel hydroxyapatite sorbent is 24775-075 5 60-180 µm cytochrome c: > 7mg/mL 5-14 Fractionation, purification of biomolecules

composed of cross-linked agarose (9); BSA: < 7mg/mL (10)HA Ultrogel beads with micro-crystals of 24775-082 25 60-180 µm cytochrome c: > 7mg/mL 5-14 Fractionation, purification of biomolecules

hydroxyapatite entrapped in the (9); BSA: < 7mg/mL (10)HA Ultrogel agarose mesh. 24775-025 100 60-180 µm cytochrome c: > 7mg/mL (9); 5-14 Fractionation, purification of biomolecules

BSA: < 7mg/mL (10)HA Ultrogel 24775-041 1000 60-180 µm cytochrome c: > 7mg/mL (9); 5-14 Fractionation, purification of biomolecules

BSA: < 7mg/mL (10)

(1) capacity determined in PBS buffer using 5 mg/mL

(2) dynamic binding capacity, 10% breakthrough, 100 cm/h, determined using 10 mg/mL hu IgG in PBS, pH 7.4; elution in 0.1 M sodium citrate, pH 2.5; column 4.6 ID x 100 mm

(3) dynamic binding capacity at 600 cm/h, using hu ATIII at 72.5 UI/mL in 20 mM Tris-HCl, 0.3 M NaCl, pH 7.4, elution with 20 mM Tris-HCl, 2 M NaCl, pH 7.4,10 cm bed height

(4) dynamic binding capacity, 10% breakthrough, 200 cm/h; sample: 5 mg/mL BSA in 50 mM Tris-HCl buffer, pH 8.6

(5) dynamic binding capacity, 10% breakthrough, 200 cm/h; sample: 5 mg/mL lysosome in 50 mM sodium acetate, pH 4.5

(6) dynamic binding capacity, 10% breakthrough, 200 cm/h; sample: 5 mg/mL hu IgG in 50 mM sodiumm acetate, 100 mM NaCl, pH 7.4

(7) dynamic binding capacity, 10% breakthrough; determined using 5 mg/mL hu IgG in PBS, flow rate: 60 cm/h

(8) dynamic binding capacity, 10% breakthrough; determined using 5 mg/mL hu polyclonal IgG; adsorbtion 50 mM sodium acetate, 0.14 M NaCl, pH 5.5,5 min residence time

(9) capacity for cytochrome c; determined using 5 mg/mL cytochrome c diluted 50/50 in 1 mM phosphate buffer, pH 6.8, at 12.5 cm/h

(10) capacity for BSA; determined using 1mg/mL BSA diluted 50/50 in 1 mM phosphate buffer, pH 6.8, at 12.5 cm/h

(11) dynamic binding capacity, 10% breakthrough determined using 5 mg/mL BSA in 50 mM Tris-HCl buffer, pH 8.6, 150 mM NaCl

(12) dynamic binding capacity, 10% breakthrough, determined using 5 mg/mL hu IgG in 50 mM sodium acetate buffer, pH 4.7, 150 mM NaCl

(13) dynamic binding capacity, 10% breakthrough at 300 cm/h, determined using 5 mg/mL Triton in PBS pH 7.4

Chromatography Product Chart